NCT01222923

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions

Single Dose Two-way Crossover Fed Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Ranbaxy Laboratories Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fed conditions.

Detailed description

A single dose two way crossover bioequivalence study in 40 normal healthy males and females was utilized to evaluate the pharmacokinetics and bioequivalence of Risperidone ODT (orally dissolving tablet) formulations. The test product was a 1 mg ODT tablet formulation of Risperidone manufactured by Ranbaxy Laboratories Ltd. The reference product was commercially available Risperidone 1 mg ODT tablets (Risperdal®), Janssen Pharmaceutica Products, LP. Each single oral dose (1 mg) will be administered orally as a 1 mg tablet. Blood samples were collected at intervals over a 72-hour period after medication administration. There was a washout period of 14 days between the two periods of the study.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Risperidone	1 mg orally disintegrating tablets

Timeline

• Start date: 2004-10-01
• Primary completion: 2004-10-01
• Completion: 2005-01-01
• First posted: 2010-10-18
• Last updated: 2010-10-18

Locations

1 site across 1 country: United States